loratadine has been researched along with ranitidine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Bakker, RA; Leurs, R; Lim, HD; Ling, P; Thurmond, RL; van Rijn, RM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dangoisse, C; Ledoux, M; Meyvisch, K | 1 |
| Milne, B; Nault, MA; Parlow, JL | 1 |
| Ng, C; Ward, E; Wolfsen, HC | 1 |
| Bhattacharyya, I; Cohen, D; Fletcher, A; Hassanein, A; Kalay Erbay, S; Lyons, R; Reeves, WH; Stewart, C; Weinstein, J; Wesson, SK | 1 |
| Cherian, M; Chew, GY; Hawkins, CA; Hurwitz, M | 1 |
| Langner, C; Siegel, C; Thonhofer, R; Trummer, M | 1 |
| Arseneau, AM; Dietrich, JJ; Hagan, LL; Moore, LM; Nesselroad, TD; Nguyen, S; Tankersley, MS | 1 |
| Dahlén, B; Dahlén, SE; Gülen, T; Hägglund, H; Nilsson, G; Sander, B | 1 |
| Brzęczek, A; Folwarczna, J; Janas, A; Pytlik, M; Śliwiński, L; Wiercigroch, M | 1 |
| Carroll, C; Hassanin, A | 1 |
1 review(s) available for loratadine and ranitidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for loratadine and ranitidine
| Article | Year |
|---|---|
Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart.
Topics: Adult; Autonomic Nervous System; Baroreflex; Double-Blind Method; Electrocardiography; Female; Heart; Heart Rate; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Loratadine; Male; Ranitidine | 2002 |
A 1-day imported fire ant rush immunotherapy schedule with and without premedication.
Topics: Adolescent; Adult; Allergens; Animals; Ants; Bites and Stings; Complex Mixtures; Desensitization, Immunologic; Female; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Loratadine; Male; Middle Aged; Prednisone; Ranitidine; Skin Tests; Young Adult | 2013 |
17 other study(ies) available for loratadine and ranitidine
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
Topics: Cell Line; Histamine Agonists; Humans; Imidazoles; Indoles; Isothiuronium; Ligands; Methylhistamines; Piperazines; Radioligand Assay; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H1; Receptors, Histamine H2; Receptors, Histamine H3; Receptors, Histamine H4 | 2005 |
Multiple eruptive keratoacanthoma and immunity disorders.
Topics: Aged; Antibodies, Antinuclear; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Immune System Diseases; Keratoacanthoma; Loratadine; Ranitidine; Recurrence | 1993 |
Medical management of Cronkhite-Canada syndrome.
Topics: Aged; Anti-Asthmatic Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Cromolyn Sodium; Drug Therapy, Combination; Fluoroquinolones; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Intestinal Polyps; Loratadine; Male; Prednisone; Ranitidine | 2002 |
Cutaneous mastocytosis in a patient with primary Sjögren's syndrome.
Topics: Adult; Autoimmunity; Biopsy; Drug Therapy, Combination; Female; Histamine H1 Antagonists, Non-Sedating; Histamine H2 Antagonists; Humans; Loratadine; Mast Cells; Mastocytosis, Cutaneous; Ranitidine; Sjogren's Syndrome; Skin; Treatment Outcome | 2006 |
Roxithromycin induced hypersensitivity pneumonitis.
Topics: Alveolitis, Extrinsic Allergic; Anti-Allergic Agents; Anti-Bacterial Agents; Drug Eruptions; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Loratadine; Middle Aged; Prednisolone; Ranitidine; Roxithromycin; Treatment Outcome | 2006 |
Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Biopsy; Chronic Disease; Diagnosis, Differential; Diarrhea; Drug Therapy, Combination; Enterocolitis; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Immunoglobulin E; Intestinal Mucosa; Loratadine; Male; Mast Cells; Mastocytosis; Methotrexate; Middle Aged; Ranitidine; Tryptases | 2011 |
Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis.
Topics: Acetates; Adult; Anaphylaxis; Cyclopropanes; Delayed Diagnosis; Drug Therapy, Combination; Epinephrine; Fatigue; Flushing; Histamine Antagonists; Humans; Leukotriene Antagonists; Loratadine; Male; Mastocytosis; Quinolines; Ranitidine; Recurrence; Sulfides | 2014 |
Modifications of histamine receptor signaling affect bone mechanical properties in rats.
Topics: Animals; Betahistine; Biomechanical Phenomena; Bone and Bones; Bone Remodeling; Calcification, Physiologic; Female; Loratadine; Ovariectomy; Ranitidine; Rats; Rats, Wistar; Receptors, Histamine; Signal Transduction | 2014 |
Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atorvastatin; Atrial Fibrillation; Bone Density Conservation Agents; Deprescriptions; Digoxin; Diltiazem; Diuretics; Drug Overdose; Factor Xa Inhibitors; Female; Furosemide; Heart Failure; Histamine H1 Antagonists, Non-Sedating; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Lisinopril; Loratadine; Metoprolol; Polypharmacy; Pyrazoles; Pyridones; Ranitidine; Syncope | 2017 |